07:00 , Sep 12, 2011 |  BC Week In Review  |  Company News

Arch Biopartners, Emory University, University of Colorado deal

Arch identified GH501a as its lead compound to treat non-small cell lung cancer (NSCLC) and pancreatic cancer. GH501a is in preclinical development at the universities. Under a 2010 deal, Arch's Colorado Cancer Therapeutics Inc. subsidiary...
08:00 , Dec 6, 2010 |  BC Week In Review  |  Company News

Arch Biopartners deal

Arch received an option to purchase the remaining 33% stake in its Colorado Cancer Therapeutics Inc. subsidiary for a total of C$800,000 (US$785,520) from two minority shareholders. Upon exercise, each shareholder will receive 500,000 common...
07:00 , Sep 27, 2010 |  BC Week In Review  |  Company News

Arch Biopartners, Emory University, University of Colorado deal

Arch subsidiary, Colorado Cancer Therapeutics Inc. acquired an option to license exclusive rights to develop and commercialize undisclosed compounds in preclinical testing to treat cancer discovered at the universities. Colorado University, who is acting as...
07:00 , Oct 26, 2009 |  BC Week In Review  |  Company News

NanoTherapies deal

On Oct. 16, biotech incubator Cancer Therapeutics Inc. said it will increase its stake in NanoTherapies to 51% from 25%. The deal includes 6 million shares of NanoTherapies' restricted stock and is expected to close...
07:00 , Jun 8, 2009 |  BC Week In Review  |  Company News

NanoTherapies deal

Cancer Therapeutics Inc. , a biotechnology incubator, will take a 25% stake in NanoTherapies. The biotech is developing calcium phosphate nanoparticles for cancer. Further terms were not disclosed. NanoTherapies LLC , Ashburn, Va.   Business:...